KalVista Pharmaceuticals, Inc.
KALVNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | $50.0M | — | — | — | $12.7M |
| Operating income | −$188.0M | −$140.4M | −$110.9M | −$96.6M | −$57.9M | −$40.5M |
| Net income | −$183.4M | −$126.6M | −$92.9M | −$82.3M | −$46.2M | −$29.1M |
| Total assets | $250.8M | $235.4M | $183.2M | $203.9M | $272.0M | $92.5M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $95.4M | $206.6M | $161.0M | $185.1M | $257.2M | $83.8M |
| EPS (diluted) | $-3.69 | $-3.44 | $-3.33 | $-3.36 | $-2.42 | $-1.64 |
| Shares out. | 50.0M | 42.7M | 34.2M | 24.6M | 24.4M | 17.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −192.3%
- Return on assets
- −73.2%
- Return on capital (ROCE)
- −91.4%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $1.91
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −12.2%clean
- Piotroski F-Score
- 1/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Jul 16, 2019
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- EKTERLYJul 3, 2025
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2026-06-30PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
- Phase 3Active Not Recruitingreadout ~2026-06-30An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Frazier Life Sciences Public Fund, L.P.Activist (13D)May 21, 2026
- Point72 Asset Management, L.P.Passive (13G)May 15, 2026
- Silverarc Capital Management, LlcPassive (13G)May 13, 2026
- Millennium Management LlcPassive (13G)May 1, 2026
- Vestal Point Capital, LpPassive (13G)Nov 14, 2025
- Tang Capital Management LlcPassive (13G)May 15, 2025
- Capital World InvestorsPassive (13G)May 13, 2025
- Venrock Healthcare Capital Partners Iii, L.P.Passive (13G)Feb 3, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 12.1M | 3.1 | -20.5% |
| Apr 30, 2026 | 15.2M | 1.8 | -22.8% |
| Apr 15, 2026 | 19.6M | 20.7 | -3.5% |
| Mar 31, 2026 | 20.4M | 15.9 | +4.8% |
| Mar 13, 2026 | 19.4M | 17.6 | +0.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Regulation FD disclosureApr 29, 2026
- Results of operationsMar 25, 2026
- Results of operations · Regulation FD disclosureJan 8, 2026
- Results of operationsNov 10, 2025
- Director / officer change · Regulation FD disclosureOct 6, 2025
- Director / officer change · Shareholder vote · Regulation FD disclosureOct 2, 2025
- Entered a material agreement · New financial obligation · Unregistered equity sale · Other material eventSep 29, 2025
- Results of operationsSep 11, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.